Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Horizon Therapeutics price target raised to $64 from $50 at Guggenheim » 07:31
07/16/20
07/16
07:31
07/16/20
07:31
HZNP

Horizon Therapeutics

$56.91 /

+0.715 (+1.27%)

Guggenheim analyst Dana…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$56.91 /

+0.715 (+1.27%)

HZNP Horizon Therapeutics
$56.91 /

+0.715 (+1.27%)

06/29/20 Jefferies
Horizon could have blockbuster in HZN-825, says Jefferies
06/10/20 Mizuho
Mizuho doctor survey shows preference for SEL-212 over Krystexxa
05/29/20 Stifel
Horizon Therapeutics price target raised to $60 from $50 at Stifel
05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
HZNP Horizon Therapeutics
$56.91 /

+0.715 (+1.27%)

Over a week ago
Recommendations
Horizon could have blockbuster in HZN-825, says Jefferies » 08:03
06/29/20
06/29
08:03
06/29/20
08:03
HZNP

Horizon Therapeutics

$54.90 /

-2.08 (-3.65%)

Jefferies analyst David…

Jefferies analyst David Steinberg noted Horizon Therapeutics recently acquired Curzion for a Phase 2 asset, now called HZN-825, that is targeting diffuse cutaneous systemic sclerosis, or dcSSc, which currently has no FDA approved treatment. While early, HZN-825 has shown encouraging safety and efficacy signals in trials, said Steinberg, who estimates peak sales for the drug of $540M, or $1.4B in peak sales in an upside scenario if the drug is "truly disease modifying." The analyst, who has not included '825 in his model without confirmatory Phase 2 data and notes that '825 is not in street estimates yet either, has a Buy rating and $63 price target on Horizon shares.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$54.90 /

-2.08 (-3.65%)

HZNP Horizon Therapeutics
$54.90 /

-2.08 (-3.65%)

06/10/20 Mizuho
Mizuho doctor survey shows preference for SEL-212 over Krystexxa
05/29/20 Stifel
Horizon Therapeutics price target raised to $60 from $50 at Stifel
05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
HZNP Horizon Therapeutics
$54.90 /

-2.08 (-3.65%)

Conference/Events
BMO Capital to hold a virtual conference » 08:41
06/23/20
06/23
08:41
06/23/20
08:41
ANTM

Anthem

$265.10 /

-1.41 (-0.53%)

, IMUX

Immunic

$14.17 /

+0.36 (+2.61%)

, SRRK

Scholar Rock

$19.09 /

+0.27 (+1.43%)

, EHC

Encompass Health

$63.73 /

-0.48 (-0.75%)

, FLXN

Flexion

$12.71 /

-0.02 (-0.16%)

, REGN

Regeneron

$627.91 /

-15.055 (-2.34%)

, SLGL

Sol-Gel Technologies

$8.44 /

+0.2 (+2.43%)

, MORF

Morphic Holding

$29.62 /

+2.45 (+9.02%)

, MNK

Mallinckrodt

$2.91 /

+0.355 (+13.89%)

, ETTX

Entasis Therapeutics

$2.99 /

-0.035 (-1.16%)

, AGTC

Applied Genetic

$6.39 /

+0.255 (+4.16%)

, HZNP

Horizon Therapeutics

$52.52 /

+2.545 (+5.09%)

, BBIO

BridgeBio

$33.07 /

+1.06 (+3.31%)

, AQST

Aquestive Therapeutics

$5.42 /

+0.01 (+0.18%)

, BTAI

BioXcel Therapeutics

$56.96 /

+4.27 (+8.10%)

, CNC

Centene

$63.09 /

-1.08 (-1.68%)

, LNTH

Lantheus

$13.99 /

-0.58 (-3.98%)

, SDGR

Schrodinger

$75.65 /

+0.49 (+0.65%)

, SCPH

scPharmaceuticals

$7.55 /

+0.35 (+4.86%)

, PHAT

Phathom Pharmaceuticals

$45.36 /

-0.635 (-1.38%)

, HUM

Humana

$379.31 /

-1.3 (-0.34%)

, HARP

Harpoon Therapeutics

$18.18 /

-0.02 (-0.11%)

Prescriptions for Success…

Prescriptions for Success Healthcare Virtual Conference will be held on June 23 at 9 am. Webcast Link

ShowHide Related Items >><<
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

MORF Morphic Holding
$29.62 /

+2.45 (+9.02%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

06/05/20 Goldman Sachs
Anthem initiated with a Neutral at Goldman Sachs
06/01/20 Piper Sandler
Kentucky contract positive for Molina, negative for Anthem, says Piper Sandler
06/01/20 Stephens
Molina Healthcare price target raised to $215 from $202 at Stephens
05/21/20 SunTrust
SunTrust raises price targets across select Healthcare Services names
IMUX Immunic
$14.17 /

+0.36 (+2.61%)

06/04/20 Wedbush
Wedbush starts Immunic at Outperform with $59 price target
06/04/20 Wedbush
Immunic initiated with an Outperform at Wedbush
05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

03/12/20
Fly Intel: Top five analyst initiations
03/11/20 Baird
Scholar Rock initiated with an Outperform at Baird
EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

05/29/20 Mizuho
Encompass Health price target lowered to $87 from $90 at Mizuho
04/20/20 BMO Capital
Encompass Health price target raised to $83 from $66 at BMO Capital
03/06/20 Deutsche Bank
Encompass Health price target raised to $83 from $73 at Deutsche Bank
03/05/20 BMO Capital
Encompass Health price target raised to $95 from $88 at BMO Capital
FLXN Flexion
$12.71 /

-0.02 (-0.16%)

05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Flexion initiated with a Buy at Guggenheim
05/08/20 Needham
Flexion price target lowered to $20 from $30 at Needham
04/02/20 Benchmark
Flexion price target lowered to $17 from $25 at Benchmark
REGN Regeneron
$627.91 /

-15.055 (-2.34%)

06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
06/12/20 Jefferies
Regeneron price target raised to $691 from $657 at Jefferies
06/02/20 Cantor Fitzgerald
Regeneron price target raised to $624 from $400 at Cantor Fitzgerald
SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
02/05/20 JMP Securities
Sol-Gel on track for two drug filings this year, says JMP Securities
12/31/19 H.C. Wainwright
Sol-Gel Technologies price target raised to $26 from $23 at H.C. Wainwright
12/31/19 BMO Capital
Sol-Gel Technologies' Twyneo result has best-in-class profile, says BMO Capital
MORF Morphic Holding
$29.62 /

+2.45 (+9.02%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

06/17/20 Citi
Sell Mallinckrodt, buy Endo with opioid risk coming back, says Citi
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight on unclear turnaround at JPMorgan
05/19/20 JPMorgan
Mallinckrodt downgraded to Underweight from Neutral at JPMorgan
04/24/20
Fly Intel: Top five analyst initiations
ETTX Entasis Therapeutics
$2.99 /

-0.035 (-1.16%)

05/08/20 BMO Capital
Entasis Therapeutics price target lowered to $5 from $15 at BMO Capital
04/14/20 H.C. Wainwright
Entasis Therapeutics price target lowered to $5 from $18 at H.C. Wainwright
08/19/19 H.C. Wainwright
Entasis Therapeutics initiated with a Buy at H.C. Wainwright
AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

06/23/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
06/22/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
02/12/20 Roth Capital
Applied Genetic in position to execute after cash raise, says Roth Capital
01/28/20
Fly Intel: Top five analyst initiations
HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

06/10/20 Mizuho
Mizuho doctor survey shows preference for SEL-212 over Krystexxa
05/29/20 Stifel
Horizon Therapeutics price target raised to $60 from $50 at Stifel
05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

06/05/20 Mizuho
HFA slide 'good' for BridgeBio, Eidos' AG10, says Mizuho
05/29/20 Piper Sandler
Piper Sandler 'encouraged' by BridgeBio data presented at ASCO
05/19/20 BTIG
BridgeBio initiated with a Buy at BTIG
05/11/20 Piper Sandler
Piper Sandler says BridgeBio's Infigratinib 'attractive candidate' for ACH
AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

05/22/20 H.C. Wainwright
Aquestive Therapeutics price target raised to $15 from $13 at H.C. Wainwright
03/16/20 Wedbush
Aquestive Therapeutics price target lowered to $31 from $36 at Wedbush
02/10/20 Wedbush
Wedbush delays launch estimates for Libervant, ups Aquestive Therapeutics target
02/10/20 Wedbush
Aquestive price target raised to $36 at Wedbush after FDA accepts NDA
BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
CNC Centene
$63.09 /

-1.08 (-1.68%)

04/29/20 Oppenheimer
Centene price target raised to $90 from $83 at Oppenheimer
04/29/20 Piper Sandler
Centene selloff yesterday a buying opportunity, says Piper Sandler
04/09/20 Jefferies
Anthem downgraded to Hold on Commercial Risk at Jefferies
LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

06/16/20 CJS Securities
Lantheus upgraded to Outperform from Market Perform at CJS Securities
10/02/19 Credit Suisse
Lantheus deal for Progenics has 'some strategic merit,' says Credit Suisse
08/16/19
Lantheus upgraded to Outperform from Market Perform at CJS Securities
SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

06/02/20 BMO Capital
Schrodinger price target raised to $85 from $67 at BMO Capital
03/02/20
Fly Intel: Top five analyst initiations
03/02/20 Jefferies
Schrodinger initiated with a Hold at Jefferies
03/02/20 Morgan Stanley
Schrodinger initiated with an Equal Weight at Morgan Stanley
SCPH scPharmaceuticals
$7.55 /

+0.35 (+4.86%)

05/13/20 SVB Leerink
scPharmaceuticals price target raised to $12 from $7 at SVB Leerink
05/13/20 H.C. Wainwright
scPharmaceuticals price target raised to $15 from $13 at H.C. Wainwright
10/15/19 H.C. Wainwright
scPharmaceuticals initiated with a Buy at H.C. Wainwright
PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

11/19/19 Evercore ISI
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/19/19 Jefferies
Phathom Pharmaceuticals initiated with a Buy at Jefferies
HUM Humana
$379.31 /

-1.3 (-0.34%)

06/18/20 Deutsche Bank
Humana price target lowered to $397 from $421 at Deutsche Bank
06/17/20 Cantor Fitzgerald
Humana price target raised to $410 from $405 at Cantor Fitzgerald
06/16/20 Cowen
Humana downgraded to Market Perform on valuation at Cowen
06/16/20 Cowen
Humana downgraded to Market Perform from Outperform at Cowen
HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

06/01/20 Wedbush
Harpoon Therapeutics price target raised to $36 from $26 at Wedbush
06/01/20 Piper Sandler
Harpoon initial data for HPN424 'highly encouraging,' says Piper Sandler
05/29/20 Roth Capital
Harpoon Therapeutics price target raised to $31 from $25 at Roth Capital
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
SRRK Scholar Rock
$19.09 /

+0.27 (+1.43%)

SLGL Sol-Gel Technologies
$8.44 /

+0.2 (+2.43%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

SCPH scPharmaceuticals
$7.55 /

+0.35 (+4.86%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

PHAT Phathom Pharmaceuticals
$45.36 /

-0.635 (-1.38%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

LNTH Lantheus
$13.99 /

-0.58 (-3.98%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HZNP Horizon Therapeutics
$52.52 /

+2.545 (+5.09%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

EHC Encompass Health
$63.73 /

-0.48 (-0.75%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

AGTC Applied Genetic
$6.39 /

+0.255 (+4.16%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

IMUX Immunic
$14.17 /

+0.36 (+2.61%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

FLXN Flexion
$12.71 /

-0.02 (-0.16%)

ETTX Entasis Therapeutics
$2.99 /

-0.035 (-1.16%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

SDGR Schrodinger
$75.65 /

+0.49 (+0.65%)

REGN Regeneron
$627.91 /

-15.055 (-2.34%)

MNK Mallinckrodt
$2.91 /

+0.355 (+13.89%)

HUM Humana
$379.31 /

-1.3 (-0.34%)

HARP Harpoon Therapeutics
$18.18 /

-0.02 (-0.11%)

CNC Centene
$63.09 /

-1.08 (-1.68%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

BBIO BridgeBio
$33.07 /

+1.06 (+3.31%)

AQST Aquestive Therapeutics
$5.42 /

+0.01 (+0.18%)

ANTM Anthem
$265.10 /

-1.41 (-0.53%)

Over a month ago
Recommendations
Mizuho doctor survey shows preference for SEL-212 over Krystexxa » 06:43
06/10/20
06/10
06:43
06/10/20
06:43
SELB

Selecta Biosciences

$4.06 /

+0.22 (+5.73%)

, HZNP

Horizon Therapeutics

$48.18 /

-0.8 (-1.63%)

Mizuho analyst Difei Yang…

Mizuho analyst Difei Yang keeps a Buy rating on Selecta Biosciences (SELB) with a $7 price target after conducting an online survey of 14 doctors that currently treat chronic refractory gout patients with Krystexxa, to better assess the market potential for SEL-212. Respondents showed a "clear preference" for Selecta's SEL-212 versus the current standard of care, Horizon Therapeutics' (HZNP) Krystexxa, Yang tells investors in a research note. Moreover, doctor's enthusiasm for SEL-212 and the combination of Krystexxa and methotrexate was high, adds the analyst. Yang is now "incrementally positive" on the market potential for SEL-212.

ShowHide Related Items >><<
SELB Selecta Biosciences
$4.06 /

+0.22 (+5.73%)

HZNP Horizon Therapeutics
$48.18 /

-0.8 (-1.63%)

SELB Selecta Biosciences
$4.06 /

+0.22 (+5.73%)

04/28/20
Fly Intel: Top five analyst initiations
04/28/20 H.C. Wainwright
Selecta Biosciences initiated with a Buy at H.C. Wainwright
03/20/20 Mizuho
Selecta COMPARE trial on track for meaningful analysis, says Mizuho
02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
HZNP Horizon Therapeutics
$48.18 /

-0.8 (-1.63%)

05/29/20 Stifel
Horizon Therapeutics price target raised to $60 from $50 at Stifel
05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
04/14/20 Piper Sandler
Horizon Therapeutics risk/reward profile 'highly attractive,' says Piper Sandler
SELB Selecta Biosciences
$4.06 /

+0.22 (+5.73%)

HZNP Horizon Therapeutics
$48.18 /

-0.8 (-1.63%)

Conference/Events
Horizon Therapeutics participates in a conference call with Piper Sandler » 04:55
06/04/20
06/04
04:55
06/04/20
04:55
HZNP

Horizon Therapeutics

$48.76 /

-1.6 (-3.18%)

Piper Sandler holds a Key…

Piper Sandler holds a Key Opinion Leader conference call on Tepezza for Thyroid Eye Disease (TED) on June 4.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$48.76 /

-1.6 (-3.18%)

HZNP Horizon Therapeutics
$48.76 /

-1.6 (-3.18%)

05/29/20 Stifel
Horizon Therapeutics price target raised to $60 from $50 at Stifel
05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
04/14/20 Piper Sandler
Horizon Therapeutics risk/reward profile 'highly attractive,' says Piper Sandler
HZNP Horizon Therapeutics
$48.76 /

-1.6 (-3.18%)

Conference/Events
Horizon Therapeutics participates in a conference call with Piper Sandler » 12:33
06/03/20
06/03
12:33
06/03/20
12:33
HZNP

Horizon Therapeutics

$49.38 /

-0.98 (-1.95%)

Piper Sandler holds a Key…

Piper Sandler holds a Key Opinion Leader conference call on Tepezza for Thyroid Eye Disease (TED) on June 4.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$49.38 /

-0.98 (-1.95%)

HZNP Horizon Therapeutics
$49.38 /

-0.98 (-1.95%)

05/29/20 Stifel
Horizon Therapeutics price target raised to $60 from $50 at Stifel
05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
04/14/20 Piper Sandler
Horizon Therapeutics risk/reward profile 'highly attractive,' says Piper Sandler
HZNP Horizon Therapeutics
$49.38 /

-0.98 (-1.95%)

Hot Stocks
Horizon Therapeutics announces a series of data presentations for Krystexxa » 08:20
06/03/20
06/03
08:20
06/03/20
08:20
HZNP

Horizon Therapeutics

$50.36 /

+0.42 (+0.84%)

Horizon Therapeutics…

Horizon Therapeutics announced a series of data presentations that demonstrate Krystexxa can be co-prescribed with three commonly used immunomodulators in rheumatology to potentially help more people with chronic gout refractory to conventional therapies achieve complete and durable response to therapy. Presentations during the European League Against Rheumatism, or EULAR, European E-Congress of Rheumatology include new data from the MIRROR open-label trial of Krystexxa with methotrexate, as well as in-practice cases and an investigator-initiated trial for two other immunomodulators with Krystexxa, all of which show high response rates. An analysis of real-world use of Krystexxa with immunomodulators will also be discussed in an oral presentation on June 4. While Krystexxa has been traditionally used as a biologic monotherapy with a clinically demonstrated impact on uncontrolled gout, recent literature suggests that using an immunomodulator such as methotrexate has the potential to increase the durability of response to Krystexxa. New data from the MIRROR open-label trial showed that when treated with oral methotrexate prior to and throughout the Krystexxa treatment period, 78.6% of patients achieved a complete response, defined as the proportion of serum uric acid, or sUA, responders during Month 6. All patients tolerated methotrexate and no new safety concerns were identified. Additional data presented during the EULAR E-Congress 2020 indicate the benefit of this enhanced therapeutic approach may extend to other commonly used immunomodulators, helping to prevent the development of anti-drug antibodies with biologics: Methotrexate addition to Krystexxa allowed most patients to complete therapy and achieve a full therapeutic response. Based on experience in a community rheumatology practice between 2017 and 2019, this chart review included 10 patients treated with a combination of Krystexxa and methotrexate. Most were treated with subcutaneous methotrexate. All 10 patients experienced a rapid decrease in serum uric acid and 80% were complete responders. Two patients discontinued treatment before infusion 12; one due to a mild infusion reaction and one lost to follow-up. A gout flare was reported in one patient and no new safety concerns were identified. Leflunomide as an immunomodulator showed high response rates with Krystexxa. This in-practice case series shows 70% achieved a complete response when co-treated with Krystexxaand leflunomide. Three patients discontinued or were lost to follow-up. The findings indicated that low-to-moderate immunomodulation could minimize or prevent the formation of anti-drug antibodies and increase the number of patients who gain the full benefit of a course of treatment, with no new safety concerns. Azathioprine with Krystexxa could increase the frequency of patients experiencing long-term lowering of serum urate. The interim data for this investigator-initiated open-label trial of 12 uncontrolled gout patients showed that at the time of data publication 60% achieved a complete response; two patients were still receiving treatment with persistent urate-lowering. No adverse events related to azathioprine were reported and gout flares were noted in six patients.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$50.36 /

+0.42 (+0.84%)

HZNP Horizon Therapeutics
$50.36 /

+0.42 (+0.84%)

05/29/20 Stifel
Horizon Therapeutics price target raised to $60 from $50 at Stifel
05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
04/14/20 Piper Sandler
Horizon Therapeutics risk/reward profile 'highly attractive,' says Piper Sandler
HZNP Horizon Therapeutics
$50.36 /

+0.42 (+0.84%)

Recommendations
Horizon Therapeutics price target raised to $60 from $50 at Stifel » 05:54
05/29/20
05/29
05:54
05/29/20
05:54
HZNP

Horizon Therapeutics

$48.72 /

-0.38 (-0.77%)

Stifel analyst Annabel…

Stifel analyst Annabel Samimy raised the firm's price target on Horizon Therapeutics to $60 from $50 and keeps a Buy rating on the shares. After speaking to Dr. Bobby Korn, oculoplastic surgeon at UCSD Shiley Eye Institute, the analyst says it was "impressive" to hear that Horizon's Tepezza has changed his treatment approach and will now be used first-line, ahead of any surgery. Thus far, Tepezza was working in all patients placed on therapy, and the doctor surmised that the drug was working beyond the immunological response and changing the biology of disease, Samimy tells investors in a research note. With a population upwards of 100,000 according to Korn, the analyst sees Tepezza's opportunity exceeding $1B in peak sales and the $200,000 expected in 2020. Samimy sees upside in Horizon Therapeutics shares.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$48.72 /

-0.38 (-0.77%)

HZNP Horizon Therapeutics
$48.72 /

-0.38 (-0.77%)

05/21/20 Piper Sandler
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler
05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
04/14/20 Piper Sandler
Horizon Therapeutics risk/reward profile 'highly attractive,' says Piper Sandler
02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
HZNP Horizon Therapeutics
$48.72 /

-0.38 (-0.77%)

Recommendations
Horizon Therapeutics price target raised to $61 from $50 at Piper Sandler » 06:37
05/21/20
05/21
06:37
05/21/20
06:37
HZNP

Horizon Therapeutics

$47.47 /

+1.28 (+2.77%)

Piper Sandler analyst…

Piper Sandler analyst David Amsellem raised the firm's price target on Horizon Therapeutics to $61 from $50 and keeps an Overweight rating on the shares. The analyst increased U.S. sales estimates for Tepezza to reflect "not only the brisk pace of initial uptake," but also what is "increasingly looking like rapid adoption" of the product as a standard-of-care option in patients with active thyroid eye disease. Early feedback from our physician checks points to early evidence of success in this population, Amsellem tells investors in a research note. The analyst believes "there is still ample room for multiple expansion" in shares of Horizon Therapeutics.

ShowHide Related Items >><<
HZNP Horizon Therapeutics
$47.47 /

+1.28 (+2.77%)

HZNP Horizon Therapeutics
$47.47 /

+1.28 (+2.77%)

05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
04/14/20 Piper Sandler
Horizon Therapeutics risk/reward profile 'highly attractive,' says Piper Sandler
02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
01/22/20 BMO Capital
Horizon Therapeutics price target raised to $46 from $40 at BMO Capita
HZNP Horizon Therapeutics
$47.47 /

+1.28 (+2.77%)

Hot Stocks
Paulson adds Kirkland Lake, exits Caesars in Q1 » 16:37
05/15/20
05/15
16:37
05/15/20
16:37
KL

Kirkland Lake Gold

$41.02 /

+0.91 (+2.27%)

, NAV

Navistar

$23.41 /

+0.77 (+3.40%)

, AEM

Agnico Eagle

$68.96 /

+2.88 (+4.36%)

, CZR

Caesars

$10.05 /

+0.185 (+1.88%)

, LOGM

LogMeln

$85.29 /

+0.23 (+0.27%)

, TIF

Tiffany

$127.06 /

-0.08 (-0.06%)

, TECD

Tech Data

$137.03 /

+0.03 (+0.02%)

, QEP

QEP Resources

$0.74 /

+0.0452 (+6.52%)

, ENDP

Endo

$3.81 /

-0.035 (-0.91%)

, NG

NovaGold

$11.71 /

+0.27 (+2.36%)

, GLD

SPDR Gold Shares

$163.95 /

+0.96 (+0.59%)

, DISCA

Discovery

$20.48 /

-0.07 (-0.34%)

, AU

AngloGold

$27.75 /

+1.71 (+6.57%)

, TSU

Tim Participacoes

$10.48 /

-0.38 (-3.50%)

, PCG

PG&E

$11.35 /

+0.245 (+2.21%)

, BHC

Bausch Health

$15.74 /

-0.2 (-1.25%)

, HZNP

Horizon Therapeutics

$47.07 /

+2.35 (+5.25%)

, TAK

Takeda Pharmaceutical

$18.60 /

-0.07 (-0.38%)

John Paulson's…

John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of March 31, 2020. The fund's two new buys during the first quarter included, by size of position, Kirkland Lake (KL) and Navistar (NAV). Paulson exited six holdings during the quarter, including by size of previous position Agnico Eagle Mines (AEM), Caesars (CZR), and LogMeIn (LOGM). The fund increased its stake in five holdings, including by size of previous position Tiffany (TIF), Tech Data (TECD), QEP Resources (QEP), Endo (ENDP), and Novagold (NG). Paulson reduced its stake in nine holdings, including by size of previous position SPDR Gold Shares (GLD), Discovery (DISCA), AngloGold Ashanti (AU), Tim Participacoes (TSU), and Pretium Resources (PVG). The fund's top holdings as of March 31, in order of size, were Bausch Health (BHC), SPDR Gold Shares, Horizon Therapeutics (HZNP), Takeda Pharmaceutical (TAK), and AngloGold Ashanti.

ShowHide Related Items >><<
TIF Tiffany
$127.06 /

-0.08 (-0.06%)

TECD Tech Data
$137.03 /

+0.03 (+0.02%)

TAK Takeda Pharmaceutical
$18.60 /

-0.07 (-0.38%)

QEP QEP Resources
$0.74 /

+0.0452 (+6.52%)

PCG PG&E
$11.35 /

+0.245 (+2.21%)

NG NovaGold
$11.71 /

+0.27 (+2.36%)

NAV Navistar
$23.41 /

+0.77 (+3.40%)

LOGM LogMeln
$85.29 /

+0.23 (+0.27%)

KL Kirkland Lake Gold
$41.02 /

+0.91 (+2.27%)

HZNP Horizon Therapeutics
$47.07 /

+2.35 (+5.25%)

GLD SPDR Gold Shares
$163.95 /

+0.96 (+0.59%)

ENDP Endo
$3.81 /

-0.035 (-0.91%)

DISCA Discovery
$20.48 /

-0.07 (-0.34%)

CZR Caesars
$10.05 /

+0.185 (+1.88%)

BHC Bausch Health
$15.74 /

-0.2 (-1.25%)

AU AngloGold
$27.75 /

+1.71 (+6.57%)

AEM Agnico Eagle
$68.96 /

+2.88 (+4.36%)

KL Kirkland Lake Gold
$41.02 /

+0.91 (+2.27%)

04/07/20 BofA
Kirkland Lake Gold initiated with a Buy at BofA
04/02/20 RBC Capital
RBC Capital maintains Outperform on Kirkland Lake Gold
03/24/20 Canaccord
Kirkland Lake Gold upgraded to Buy from Hold at Canaccord
03/18/20 CIBC
Kirkland Lake Gold upgraded to Outperformer from Neutral at CIBC
NAV Navistar
$23.41 /

+0.77 (+3.40%)

05/07/20 Longbow
Navistar likely to beat near-term expectations, says Longbow
04/17/20 JPMorgan
Truck cancellation rate in March hits high at 43%, says JPMorgan
04/03/20 JPMorgan
Class 8 truck orders dropped 51% in March, says JPMorgan
03/17/20 Baird
Baird says 'great opportunity' to get back involved with Navistar
AEM Agnico Eagle
$68.96 /

+2.88 (+4.36%)

05/01/20 TD Securities
Agnico Eagle price target lowered to C$76 from C$77 at TD Securities
05/01/20 BMO Capital
Agnico Eagle price target raised to C$60 from C$54 at BMO Capital
05/01/20 CIBC
CIBC backs Outperformer on Agnico Eagle after 'solid' Q1 results
05/01/20 RBC Capital
Agnico Eagle's Q1 results mixed relative to expectations, says RBC Capital
CZR Caesars
$10.05 /

+0.185 (+1.88%)

05/12/20 Deutsche Bank
Caesars price target lowered to $11 from $13 at Deutsche Bank
05/12/20 Jefferies
Eldorado Resorts price target raised to $38 from $29 at Jefferies
04/17/20 SunTrust
Caesars, Twin River Worldwide upgraded to Buy from Hold at SunTrust
04/17/20 SunTrust
Caesars upgraded to Buy from Hold at SunTrust
LOGM LogMeln
$85.29 /

+0.23 (+0.27%)

01/15/20 Piper Sandler
Piper introduces long VMware, short Juniper pair trade into Q4 results
01/03/20
Fly Intel: Top five analyst downgrades
01/03/20
LogMeln downgraded to Sector Weight from Overweight at KeyBanc
01/02/20 KeyBanc
LogMeln downgraded to Sector Weight from Overweight at KeyBanc
TIF Tiffany
$127.06 /

-0.08 (-0.06%)

12/09/19 Cowen
Tiffany downgraded to Market Perform from Outperform at Cowen
12/06/19
Fly Intel: Top five analyst downgrades
12/06/19 Loop Capital
Tiffany price target raised to $135 from $85 at Loop Capital
12/06/19 Credit Suisse
Tiffany's best path forward likely the LVMH deal, says Credit Suisse
TECD Tech Data
$137.03 /

+0.03 (+0.02%)

03/18/20 Northcoast
Tech Data upgraded to Buy from Neutral at Northcoast
12/10/19 Northcoast
Tech Data downgraded to Neutral from Buy at Northcoast
10/17/19 Loop Capital
Tech Data price target raised to $150 from $130 at Loop Capital
10/16/19 Stifel
Tech Data investors likely to want higher takeout price, says Stifel
QEP QEP Resources
$0.74 /

+0.0452 (+6.52%)

04/07/20 Scotiabank
QEP Resources downgraded to Underperform from Sector Perform at Scotiabank
03/31/20 Piper Sandler
QEP Resources downgraded to Underweight from Neutral at Piper Sandler
03/20/20 Stephens
Stephens upgrades Hess, downgrades 11 others in E&P following oil's melt down
03/20/20 Stephens
QEP Resources downgraded to Equal Weight from Overweight at Stephens
ENDP Endo
$3.81 /

-0.035 (-0.91%)

04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Endo initiated with a Buy at Citi
01/03/20 Piper Sandler
Endo upgraded to Overweight from Neutral at Piper Jaffray
09/11/19 Guggenheim
Endo assumed with a Neutral at Guggenheim
NG NovaGold
$11.71 /

+0.27 (+2.36%)

GLD SPDR Gold Shares
$163.95 /

+0.96 (+0.59%)

DISCA Discovery
$20.48 /

-0.07 (-0.34%)

05/14/20 Barrington
Discovery price target lowered to $28 from $34 at Barrington
04/27/20 RBC Capital
Discovery initiated with an Outperform at RBC Capital
04/23/20 Evercore ISI
Discovery downgraded to In Line from Outperform at Evercore ISI
04/17/20 Citi
Discovery price target lowered to $27 from $39 at Citi
AU AngloGold
$27.75 /

+1.71 (+6.57%)

04/21/20 BofA
AngloGold upgraded to Neutral from Underperform at BofA
02/06/20 UBS
AngloGold initiated with a Neutral at UBS
10/18/19 Goldman Sachs
AngloGold upgraded to Buy from Neutral at Goldman Sachs
06/27/19 BMO Capital
AngloGold upgraded to Outperform from Market Perform at BMO Capital
TSU Tim Participacoes
$10.48 /

-0.38 (-3.50%)

04/21/20 HSBC
Tim Participacoes upgraded to Hold from Reduce at HSBC
01/24/20 HSBC
Tim Participacoes downgraded to Reduce from Hold at HSBC
08/01/19 Barclays
Barclays upgrades Tim Participacoes to Overweight, downgrades Telefonica Brasil
08/01/19 Barclays
Tim Participacoes upgraded to Overweight from Equal Weight at Barclays
PCG PG&E
$11.35 /

+0.245 (+2.21%)

05/15/20 Barclays
Barclays upgrades Utilities sector along with PG&E and two others
05/15/20 Barclays
PG&E upgraded to Overweight from Equal Weight at Barclays
05/06/20 Mizuho
PG&E price target raised to $13.50 from $12.50 at Mizuho
05/04/20
Fly Intel: Top five analyst upgrades
BHC Bausch Health
$15.74 /

-0.2 (-1.25%)

04/24/20 Citi
Bausch Health initiated with a Buy at Citi
04/02/20 Morgan Stanley
Bausch Health downgraded to Equal Weight with $17 price target at Morgan Stanley
04/02/20 Morgan Stanley
Bausch Health downgraded to Equal Weight from Overweight at Morgan Stanley
HZNP Horizon Therapeutics
$47.07 /

+2.35 (+5.25%)

05/08/20 Morgan Stanley
Horizon Therapeutics price target raised to $50 from $39 at Morgan Stanley
04/14/20 Piper Sandler
Horizon Therapeutics risk/reward profile 'highly attractive,' says Piper Sandler
02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
01/22/20 BMO Capital
Horizon Therapeutics price target raised to $46 from $40 at BMO Capita
TAK Takeda Pharmaceutical
$18.60 /

-0.07 (-0.38%)

04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
03/25/20 Stifel
Molecular Templates initiated with a Buy at Stifel
02/25/20 Stifel
Iovance among 'more interesting' cell therapy takeout candidates, says Stifel
TIF Tiffany
$127.06 /

-0.08 (-0.06%)

TECD Tech Data
$137.03 /

+0.03 (+0.02%)

TAK Takeda Pharmaceutical
$18.60 /

-0.07 (-0.38%)

QEP QEP Resources
$0.74 /

+0.0452 (+6.52%)

PCG PG&E
$11.35 /

+0.245 (+2.21%)

NAV Navistar
$23.41 /

+0.77 (+3.40%)

LOGM LogMeln
$85.29 /

+0.23 (+0.27%)

KL Kirkland Lake Gold
$41.02 /

+0.91 (+2.27%)

HZNP Horizon Therapeutics
$47.07 /

+2.35 (+5.25%)

ENDP Endo
$3.81 /

-0.035 (-0.91%)

DISCA Discovery
$20.48 /

-0.07 (-0.34%)

CZR Caesars
$10.05 /

+0.185 (+1.88%)

BHC Bausch Health
$15.74 /

-0.2 (-1.25%)

AEM Agnico Eagle
$68.96 /

+2.88 (+4.36%)

TIF Tiffany
$127.06 /

-0.08 (-0.06%)

TECD Tech Data
$137.03 /

+0.03 (+0.02%)

TAK Takeda Pharmaceutical
$18.60 /

-0.07 (-0.38%)

PCG PG&E
$11.35 /

+0.245 (+2.21%)

NAV Navistar
$23.41 /

+0.77 (+3.40%)

LOGM LogMeln
$85.29 /

+0.23 (+0.27%)

KL Kirkland Lake Gold
$41.02 /

+0.91 (+2.27%)

ENDP Endo
$3.81 /

-0.035 (-0.91%)

DISCA Discovery
$20.48 /

-0.07 (-0.34%)

CZR Caesars
$10.05 /

+0.185 (+1.88%)

TIF Tiffany
$127.06 /

-0.08 (-0.06%)

TECD Tech Data
$137.03 /

+0.03 (+0.02%)

QEP QEP Resources
$0.74 /

+0.0452 (+6.52%)

PCG PG&E
$11.35 /

+0.245 (+2.21%)

NAV Navistar
$23.41 /

+0.77 (+3.40%)

LOGM LogMeln
$85.29 /

+0.23 (+0.27%)

KL Kirkland Lake Gold
$41.02 /

+0.91 (+2.27%)

ENDP Endo
$3.81 /

-0.035 (-0.91%)

DISCA Discovery
$20.48 /

-0.07 (-0.34%)

CZR Caesars
$10.05 /

+0.185 (+1.88%)

BHC Bausch Health
$15.74 /

-0.2 (-1.25%)

TIF Tiffany
$127.06 /

-0.08 (-0.06%)

TAK Takeda Pharmaceutical
$18.60 /

-0.07 (-0.38%)

PCG PG&E
$11.35 /

+0.245 (+2.21%)

NG NovaGold
$11.71 /

+0.27 (+2.36%)

LOGM LogMeln
$85.29 /

+0.23 (+0.27%)

KL Kirkland Lake Gold
$41.02 /

+0.91 (+2.27%)

GLD SPDR Gold Shares
$163.95 /

+0.96 (+0.59%)

ENDP Endo
$3.81 /

-0.035 (-0.91%)

DISCA Discovery
$20.48 /

-0.07 (-0.34%)

CZR Caesars
$10.05 /

+0.185 (+1.88%)

BHC Bausch Health
$15.74 /

-0.2 (-1.25%)

AEM Agnico Eagle
$68.96 /

+2.88 (+4.36%)

GLD SPDR Gold Shares
$163.95 /

+0.96 (+0.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.